Friday, 24 July 2015
A systemic immunomodulator IMM-101 extends survival and maintains quality of life in the IMAGE1 study
The survival benefits in patients with advanced pancreatic cancer treated with a systemic immunomodulator, IMM‑101 plus gemcitabine in a randomised, open-label phase II IMAGE1 trial were accompanied by an improvement in several quality of life (QoL) scores. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment